Eli Lilly saw its shares close down 6.6% at $744.91 yesterday, after it revealed forecast for sales at the JP Morgan ...

Cases of avian influenza A (H5N1) continue to rise among cattle and humans in the USA. Scientists and government health ...

Belgian drugmaker UCB has presented what it calls its ‘growth journey’ and the strategic priorities driving future success at ...

Privately-held Italian drugmaker Menarini and its oncology-focused subsidiary Stemline Therapeutics have entered into a ...

Shares of US biotech Regenxbio surged 18.4% in pre-open trading Tuesday after announced a strategic partnership with Japan’s ...

Japanese drugmaker Daiichi Sankyo announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property ...

Several of the USA’s biggest pharmacy benefit managers (PBMs) have generated billions of dollars in revenue by charging ...

Verastem Oncology licenses VS-7375 rights from GenFleet Therapeutics, aiming to target KRAS-driven cancers. Early Phase I ...

Mabwell Bioscience plans a secondary listing in Hong Kong to bolster development and global expansion. The move targets Hong ...

Seattle, USA- based clinical-stage CART-T therapies developer Umoja Biopharma, today announced the closing of a $100 million ...

Turkish drugmaker Er-Kim has signed a distribution agreement with Germany’s MEDICE Health Family to commercialize Vafseo ...

US late-stage biopharma firm Sling Therapeutics today announced top-line efficacy and safety data from the Phase IIb/III LIDS ...